Analyst Price Targets — ALKS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2026 9:04 am | Vamil Divan | Mizuho Securities | $65.00 | $51.72 | StreetInsider | Alkermes (ALKS) PT Raised to $65 at Mizuho |
| June 18, 2026 11:05 am | Ami Fadia | Needham | $54.00 | $44.51 | StreetInsider | Alkermes (ALKS) PT Raised to $54 at Needham |
| June 9, 2026 11:33 am | Leonid Timashev | RBC Capital | $56.00 | $44.08 | StreetInsider | Alkermes (ALKS) PT Raised to $56 at RBC Capital; 'Don't Sleep On The Pipeline' |
| May 6, 2026 1:45 pm | — | Needham | $50.00 | $35.62 | TheFly | Alkermes price target raised to $50 from $45 at Needham |
| February 26, 2026 11:39 am | Douglas Tsao | H.C. Wainwright | $43.00 | $31.04 | StreetInsider | Alkermes (ALKS) PT Lowered to $43 at H.C. Wainwright |
| February 23, 2026 9:09 pm | — | Wolfe Research | $45.00 | $32.19 | TheFly | Alkermes initiated with an Outperform at Wolfe Research |
| October 28, 2025 5:16 pm | Akash Tewari | Jefferies | $56.00 | $30.75 | StreetInsider | Jefferies on Alkermes (ALKS) Earnings: 'Solid Q3 + FY guide raise' |
| October 27, 2025 11:49 am | — | Mizuho Securities | $45.00 | $29.76 | TheFly | Alkermes price target raised to $45 from $40 at Mizuho |
| October 23, 2025 10:29 am | David Amsellem | Piper Sandler | $45.00 | $31.09 | TheFly | Alkermes price target raised to $45 from $38 at Piper Sandler |
| October 22, 2025 6:48 pm | — | RBC Capital | $47.00 | $31.09 | TheFly | Alkermes price target raised to $47 from $45 at RBC Capital |
Latest News for ALKS
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for…
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of…
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06. Over the past week, shares increased by 9.0%, and have seen
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALKS.
U.S. House Trading
No House trades found for ALKS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.